OTR-AC

OTR-AC is the acetate ester of ostarine, also known as enobosarm, GTx-024, or S-22, a nonsteroidal selective androgen receptor modulator (SARM). The ester is designed to release enobosarm in the body, and it is promoted as offering greater potency per milligram than the base compound. Enobosarm itself is widely regarded as the most clinically characterized SARM, having progressed through Phase I, II, and III clinical testing ^[2][4].

SARMs are a class of anabolic agents that bind the androgen receptor and exhibit tissue selectivity; they modulate the same anabolic pathways as classical androgens but, within their effective dose range, increase muscle mass and physical function while largely sparing androgenic effects on tissues such as the prostate, skin, and hair. Unlike testosterone, enobosarm is orally active, nonaromatizable, nonvirilizing, and tissue-selective, which is the central rationale for its development ^[3][4].

The clinical evidence for enobosarm is substantial. A double-blind, placebo-controlled Phase 2 trial in patients with cancer found that enobosarm significantly increased total lean body mass compared with baseline, with a median gain of about 1.5 kg at the 1 mg dose, without the toxic effects associated with androgens ^[1]. The Phase 3 POWER program evaluated enobosarm at 3 mg once daily for the prevention and treatment of muscle wasting in non-small-cell lung cancer, using lean body mass and stair climb power as co-primary endpoints ^[2]. Earlier work established its activity in cancer cachexia ^[3], and it received FDA fast track designation for muscle wasting ^[4]; SARMs including enobosarm have also increased pelvic floor muscle mass in preclinical models ^[5].

OTR-AC itself is sold as a research chemical and is not an approved medication; enobosarm remains investigational. As an androgen receptor modulator, the ester carries the class considerations of possible reductions in HDL cholesterol and suppression of natural testosterone, so routine monitoring is prudent for anyone studying it.

OTR-AC is an ester form of the SARM enobosarm (ostarine) with essentially no dedicated human safety data; like other SARMs it is expected to suppress endogenous testosterone, lower HDL cholesterol, and potentially strain the liver. It is not an approved medicine and is prohibited in sport, and the pharmacology and purity of research-grade material are not validated. Its long-term risks in humans are unknown.

OTR-AC is an acetate ester of ostarine (enobosarm), and its history is largely the history of that parent molecule; enobosarm itself was developed by the Memphis biotechnology firm GTx out of selective androgen receptor modulator chemistry pioneered by James Dalton and Duane Miller, and it became the most clinically characterized SARM through randomized trials and the Phase 3 POWER program in cancer-related muscle wasting. The acetate ester is a delivery modification rather than a separately developed drug; adding the ester is intended to alter absorption and increase potency per milligram, releasing ostarine after administration.

Unlike enobosarm, OTR-AC has not been the subject of its own formal clinical development program, and documentation specific to the ester form is limited, drawn mainly from the research-chemical and performance market rather than peer-reviewed pharmacology. Its evidentiary foundation therefore rests on the well-studied clinical record of enobosarm, described in the Phase 2 trial published in 2013 and the Phase 3 design papers that followed.

OTR-AC is positioned as a more potent, milligram-for-milligram delivery form of the best-documented SARM, which gives it borrowed credibility from enobosarm's strong clinical track record of building lean body mass and physical function while sparing the prostate and other tissues that classical steroids affect. For users drawn to muscle-directed anabolism without aromatization or virilization, that underlying profile is genuinely attractive, and the reported goal of the ester, greater potency at a smaller dose, is a coherent pharmaceutical idea.

The candid limitation is that the ester itself has not been independently trialed, so claims about its added potency rest on formulation logic rather than published head-to-head data. As with all SARMs, the same androgen-receptor biology that builds muscle can nudge HDL cholesterol down and suppress endogenous testosterone, making lipids, liver enzymes, and natural testosterone worth monitoring, and it remains an unapproved research compound rather than a licensed medicine.